OLFML2B

Across TCGA pan-cancer cohorts, OLFML2B Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated OLFML2B data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OLFML2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OLFML2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, PAAD, and SCLC are the cancer types where OLFML2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.710	.002	30	view →
PAAD	OS	Median	All	0.060	0.641	<.001	24	view →
SCLC	OS	Median	II,III,IV	0.178	0.712	<.001	24	view →
COAD	OS	Median	III,IV	0.082	0.792	<.001	24	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.155	0.701	.001	12	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.922	0.436	.023	6	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

OLFML2B–HNSC (OS)

Open the HNSC breakdown →